Medline to Present at Barclays Global Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy MDLN?
Source: Newsfilter
- Executive Attendance: Medline's CEO Jim Boyle and CFO Mike Drazin are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach on March 11, 2026, showcasing the company's leadership in the healthcare sector.
- Webcast Arrangement: The presentation will be available via a live webcast on Medline's Investor Relations website, allowing global investors to stay updated on the company's latest developments in real-time.
- Replay Availability: Following the presentation, the webcast will be accessible on Medline's Investor Relations website for six months, ensuring that investors who miss the live event can still obtain relevant information, thereby enhancing transparency.
- Company Background: Medline is the largest provider of medical-surgical products and supply chain solutions, employing over 43,000 people and operating in more than 100 countries, dedicated to improving clinical, financial, and operational outcomes for healthcare providers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDLN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDLN
Wall Street analysts forecast MDLN stock price to rise
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.510
Low
42.00
Averages
47.92
High
52.00
Current: 47.510
Low
42.00
Averages
47.92
High
52.00
About MDLN
Medline Inc. is a provider of medical-surgical products and supply chain solutions serving all points of care. The Company delivers mission-critical products used daily across the full range of care settings, from hospitals and surgery centers to physician offices and post-acute facilities. It operates through two segments: Medline Brand and Supply Chain Solutions. These segments offer approximately 335,000 medical-surgical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care, wound care, and consumable lab and diagnostics products. Its Medline Brand products are organized into three product categories: Front Line Care, Surgical Solutions, and Laboratory and Diagnostics. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands and also provides tailored logistics and supply chain optimization services to domestic and international consumers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medline Reports Mixed Q4 Results with Strong Sales but Earnings Miss
- Earnings Overview: Medline Inc reported a quarterly loss of $0.01 per share, missing the analyst consensus estimate of $0.18 per share, indicating pressure on profitability.
- Sales Performance: The company achieved quarterly sales of $7.787 billion, exceeding the analyst consensus estimate of $7.547 billion, demonstrating strong market demand and reinforcing its position in the healthcare sector.
- Customer Signing Update: CEO Jim Boyle noted that total new customer signings reached $2.4 billion for 2025, reflecting customer confidence in Medline's value, service, and reliability, enhancing the company's capability to support health systems.
- Stock Price Reaction: Following the earnings announcement, Medline's shares rose by 3.4% to $49.80, indicating market optimism regarding the company's future prospects.
See More
Medline Inc. Raises $6.26 Billion in Successful IPO
- Earnings Report: Medline Inc.'s Q4 results reveal a GAAP EPS of -$0.01, missing expectations by $0.14, while revenue reached $7.8 billion, up 14.8% year-over-year, exceeding forecasts by $290 million, indicating robust market performance.
- Growth Drivers: The revenue increase was primarily driven by strong growth in both the Medline Brand and Supply Chain Solutions segments, highlighting sustained demand in the medical supply sector and enhancing the company's competitive position.
- Future Outlook: The company anticipates organic sales growth of 8% to 9% for 2026, with adjusted EBITDA projected between $3.5 billion and $3.6 billion, reflecting management's confidence in future performance and ongoing growth potential.
- Successful IPO: Medline Inc. successfully raised $6.26 billion in its IPO at a price of $29 per share, with the stock surging 28%, demonstrating strong market confidence in its business model and growth prospects.
See More
Stock Movers: Nvidia, Paramount, First Solar, Workday, Axon, HP Inc., Lucid, and Others
- Stock Market Movement: Stock futures were rising on Wednesday, indicating positive investor sentiment.
- Response to Political Events: Investors appeared to overlook President Donald Trump’s State of the Union address, focusing instead on market trends.
See More
Medline Inc. Raises $6.26 Billion in Successful IPO
- Strong IPO Performance: Medline Inc. successfully raised $6.26 billion in its IPO by pricing shares at $29 each, reflecting strong market confidence in its business model and providing ample funding for future expansion.
- High Market Demand: The IPO attracted significant investor interest, with shares surging 28% upon opening, indicating strong recognition of Medline's growth potential and profitability in the medical supply sector, which may further enhance its market share.
- Earnings Forecast: Medline is set to announce its Q4 earnings on February 25, with consensus estimates predicting an EPS of $0.24 and revenue of $7.51 billion, providing crucial insights into the company's financial health for investors.
- Strengthened Industry Position: Medline boasts a solid physical moat in the medical supply industry, and with visible earnings growth, the company is poised for sustained market expansion and revenue growth in the coming years.
See More
Bank of America Names Five Must-Have Stocks
- Evercore Strong Performance: Evercore's recent quarterly earnings report showed strong top and bottom line beats, with analyst Ebrahim Poonawala noting that the firm's exposure to large-cap M&A and growth in non-M&A advisory revenues will support EPS growth, making it a compelling investment opportunity.
- Live Nation Growth Potential: Live Nation is viewed as a leader in global live entertainment, with analyst Peter Henderson highlighting robust demand and healthy consumer spending trends that will underpin its medium to long-term growth; despite regulatory pressures, the stock remains attractive, having risen 16% in the past month.
- Medline Market Leader: Analyst Andrew Obin initiated coverage of Medline with a buy rating, forecasting sustainable high-single digit organic growth driven by market share gains in the $175 billion U.S. market, with the stock up 13% over the past month.
- Waystar Steady Growth: Waystar is well-positioned for steady growth supported by stable end-market demand for revenue cycle management solutions, with analysts believing the company can expand relationships with 18 of the top 22 hospitals, driving further growth opportunities.
See More
Medline to Present at Barclays Global Healthcare Conference
- Executive Attendance: Medline's CEO Jim Boyle and CFO Mike Drazin are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach on March 11, 2026, showcasing the company's leadership in the healthcare sector.
- Webcast Arrangement: The presentation will be available via a live webcast on Medline's Investor Relations website, allowing global investors to stay updated on the company's latest developments in real-time.
- Replay Availability: Following the presentation, the webcast will be accessible on Medline's Investor Relations website for six months, ensuring that investors who miss the live event can still obtain relevant information, thereby enhancing transparency.
- Company Background: Medline is the largest provider of medical-surgical products and supply chain solutions, employing over 43,000 people and operating in more than 100 countries, dedicated to improving clinical, financial, and operational outcomes for healthcare providers.
See More
Medline Reports Mixed Q4 Results with Strong Sales but Earnings Miss
- Earnings Overview: Medline Inc reported a quarterly loss of $0.01 per share, missing the analyst consensus estimate of $0.18 per share, indicating pressure on profitability.
- Sales Performance: The company achieved quarterly sales of $7.787 billion, exceeding the analyst consensus estimate of $7.547 billion, demonstrating strong market demand and reinforcing its position in the healthcare sector.
- Customer Signing Update: CEO Jim Boyle noted that total new customer signings reached $2.4 billion for 2025, reflecting customer confidence in Medline's value, service, and reliability, enhancing the company's capability to support health systems.
- Stock Price Reaction: Following the earnings announcement, Medline's shares rose by 3.4% to $49.80, indicating market optimism regarding the company's future prospects.
See More
Medline Inc. Raises $6.26 Billion in Successful IPO
- Earnings Report: Medline Inc.'s Q4 results reveal a GAAP EPS of -$0.01, missing expectations by $0.14, while revenue reached $7.8 billion, up 14.8% year-over-year, exceeding forecasts by $290 million, indicating robust market performance.
- Growth Drivers: The revenue increase was primarily driven by strong growth in both the Medline Brand and Supply Chain Solutions segments, highlighting sustained demand in the medical supply sector and enhancing the company's competitive position.
- Future Outlook: The company anticipates organic sales growth of 8% to 9% for 2026, with adjusted EBITDA projected between $3.5 billion and $3.6 billion, reflecting management's confidence in future performance and ongoing growth potential.
- Successful IPO: Medline Inc. successfully raised $6.26 billion in its IPO at a price of $29 per share, with the stock surging 28%, demonstrating strong market confidence in its business model and growth prospects.
See More
Stock Movers: Nvidia, Paramount, First Solar, Workday, Axon, HP Inc., Lucid, and Others
- Stock Market Movement: Stock futures were rising on Wednesday, indicating positive investor sentiment.
- Response to Political Events: Investors appeared to overlook President Donald Trump’s State of the Union address, focusing instead on market trends.
See More
Medline Inc. Raises $6.26 Billion in Successful IPO
- Strong IPO Performance: Medline Inc. successfully raised $6.26 billion in its IPO by pricing shares at $29 each, reflecting strong market confidence in its business model and providing ample funding for future expansion.
- High Market Demand: The IPO attracted significant investor interest, with shares surging 28% upon opening, indicating strong recognition of Medline's growth potential and profitability in the medical supply sector, which may further enhance its market share.
- Earnings Forecast: Medline is set to announce its Q4 earnings on February 25, with consensus estimates predicting an EPS of $0.24 and revenue of $7.51 billion, providing crucial insights into the company's financial health for investors.
- Strengthened Industry Position: Medline boasts a solid physical moat in the medical supply industry, and with visible earnings growth, the company is poised for sustained market expansion and revenue growth in the coming years.
See More
Bank of America Names Five Must-Have Stocks
- Evercore Strong Performance: Evercore's recent quarterly earnings report showed strong top and bottom line beats, with analyst Ebrahim Poonawala noting that the firm's exposure to large-cap M&A and growth in non-M&A advisory revenues will support EPS growth, making it a compelling investment opportunity.
- Live Nation Growth Potential: Live Nation is viewed as a leader in global live entertainment, with analyst Peter Henderson highlighting robust demand and healthy consumer spending trends that will underpin its medium to long-term growth; despite regulatory pressures, the stock remains attractive, having risen 16% in the past month.
- Medline Market Leader: Analyst Andrew Obin initiated coverage of Medline with a buy rating, forecasting sustainable high-single digit organic growth driven by market share gains in the $175 billion U.S. market, with the stock up 13% over the past month.
- Waystar Steady Growth: Waystar is well-positioned for steady growth supported by stable end-market demand for revenue cycle management solutions, with analysts believing the company can expand relationships with 18 of the top 22 hospitals, driving further growth opportunities.
See More
Medline to Present at Barclays Global Healthcare Conference
- Executive Attendance: Medline's CEO Jim Boyle and CFO Mike Drazin are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach on March 11, 2026, showcasing the company's leadership in the healthcare sector.
- Webcast Arrangement: The presentation will be available via a live webcast on Medline's Investor Relations website, allowing global investors to stay updated on the company's latest developments in real-time.
- Replay Availability: Following the presentation, the webcast will be accessible on Medline's Investor Relations website for six months, ensuring that investors who miss the live event can still obtain relevant information, thereby enhancing transparency.
- Company Background: Medline is the largest provider of medical-surgical products and supply chain solutions, employing over 43,000 people and operating in more than 100 countries, dedicated to improving clinical, financial, and operational outcomes for healthcare providers.
See More
